Hillsdale Investment Management Inc. Makes New Investment in Globus Medical, Inc. $GMED

Hillsdale Investment Management Inc. bought a new position in Globus Medical, Inc. (NYSE:GMED) during the 4th quarter, Holdings Channel.com reports. The institutional investor bought 41,500 shares of the medical device company’s stock, valued at approximately $3,623,000.

Several other large investors have also recently added to or reduced their stakes in GMED. Advisory Services Network LLC acquired a new stake in Globus Medical in the third quarter worth $26,000. EverSource Wealth Advisors LLC increased its position in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock worth $27,000 after buying an additional 197 shares during the period. SBI Securities Co. Ltd. increased its position in Globus Medical by 98.2% in the fourth quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock worth $29,000 after buying an additional 167 shares during the period. Parallel Advisors LLC increased its position in Globus Medical by 45.1% in the third quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock worth $32,000 after buying an additional 173 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Globus Medical in the third quarter worth $36,000. 95.16% of the stock is owned by institutional investors and hedge funds.

Globus Medical Stock Performance

NYSE:GMED opened at $82.00 on Monday. Globus Medical, Inc. has a 1 year low of $51.79 and a 1 year high of $101.40. The stock has a market cap of $11.13 billion, a price-to-earnings ratio of 19.07, a PEG ratio of 1.69 and a beta of 0.95. The business has a fifty day moving average of $87.01 and a 200-day moving average of $88.43.

Globus Medical (NYSE:GMED) last announced its quarterly earnings data on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.20. The business had revenue of $759.85 million during the quarter, compared to analyst estimates of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The company’s revenue was up 27.0% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. On average, equities research analysts predict that Globus Medical, Inc. will post 4.74 EPS for the current year.

Wall Street Analysts Forecast Growth

GMED has been the subject of several recent analyst reports. Zacks Research raised Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Wells Fargo & Company decreased their price target on Globus Medical from $104.00 to $103.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Barclays increased their price target on Globus Medical from $118.00 to $123.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 25th. Needham & Company LLC increased their price target on Globus Medical from $114.00 to $117.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Finally, Royal Bank Of Canada increased their price target on Globus Medical from $115.00 to $120.00 and gave the stock an “outperform” rating in a research note on Friday, May 8th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Globus Medical has a consensus rating of “Moderate Buy” and an average target price of $106.36.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.